Will Actos Remain on Market in Europe?
July 13, 2011, by Ronald V. Miller, Jr.
European Medicines Agency (EMA) - which is basically Europe's FDA - will decide this month whether the diabetes drug Actos should remain on the market or not due to a possible link to bladder cancer.
Last month, France and Germany jumped ahead of the rest of the continent and suspended the use of Actos after a study indicated Actos users may have a higher risk of bladder cancer.
Here, the FDA says it will add information about the potential risk of bladder cancer after long-term use to the drug's label, while keeping the product on the market at least for the time being.
- Overview of potential Actos lawsuits
- What Canada is doing about Actos?
